Clinical trials: Adenocarcinoma of the Prostate Stage III
Prostate Cancer
Chemotherapy Plus Hormone Therapy Versus Androgen Suppression in Treating Patients With Metastatic or Unresectable Prostate Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining hormone therapy with chemotherapy and androgen suppression may kill more tumor cells.
- Trial name
- NCT00002855
- Testing
- Bicalutamide, Doxorubicin hydrochloride, Estramustine Phosphate Sodium
- Where
- United States
- Volunteers
- 306 people
- Sponsor
- M.D. Anderson Cancer Center
Prostate Cancer, Adenocarcinoma
A Long Term Safety Study With Atrasentan
The primary purpose of the study is to evaluate long-term safety and tolerability of atrasentan 10 mg in men with hormone refractory prostate cancer.
- Trial name
- NCT00127478
- Testing
- Atrasentan
- Where
- 15 sites in United States, Canada and 3 more
- Volunteers
- 166 people
- Sponsor
- Abbott